In: Cellular and Molecular Life Sciences, 2007, vol. 64, no. 24, p. 3261-3265
|
In: Cellular and Molecular Life Sciences CMLS, 2003, vol. 60, no. 12, p. 2547-2560
|
In: Brain, 1999, vol. 122, no. 8, p. 1563-1577
|
In: Brain, 2012, vol. 135, no. 5, p. 1395-1411
|
In: Brain, 2014, vol. 137, no. 3, p. 668-682
|
In: Brain, 2012, vol. 135, no. 12, p. 3567-3583
|
In: Journal of Neuropathology & Experimental Neurology, 2010, vol. 69, no. 3, p. 281-293
Muscle weakness in Charcot-Marie-Tooth Type 1A disease (CMT1A) caused by mutations in peripheral myelin protein 22 (PMP22) has been attributed to an axonopathy that results in denervation and muscle atrophy. The underlying pathophysiological mechanisms involved are not understood. We investigated motor performance, neuromuscular junctions (NMJs), physiological parameters, and muscle morphometry...
|